Open Access
SHS Web Conf.
Volume 149, 2022
International Conference on Social Science 2022 “Integrating Social Science Innovations on Post Pandemic Through Society 5.0” (ICSS 2022)
Article Number 03045
Number of page(s) 6
Section Social Science
Published online 18 November 2022
  1. A. Susilo et al., “Corona virus Disease 2019: Review of Current Literatures,” (2020). [Online]. Available: [Google Scholar]
  2. S. Roy, “Economic Impact of Covid-19 Pandemic,” R-Economy, Vol. 6, No. 3, pp. 183– 195, (2020), doi:10.15826/recon.2020.6.3.016 [Google Scholar]
  3. S. Revinka, “Pengaruh Pandemi Covid-19 Terhadap Nilai Perusahaan Pada Sebelas Sektor Di Bursa Efek Indonesia (BEI),” J. Acitya Ardana, Vol. 1, No. 2, pp. 145–163, (2021), doi:10.31092/jaa.v1i2.1334 [CrossRef] [Google Scholar]
  4. H. Sholichah and S. Johan, “The Effect of First Case Covid-19 announcement on Average Trading Volume Activity of Pharmaceutical Sector Companies,” J. Manaj. Bisnis dan Kewirausahaan, Vol. 6, pp. 218–224, (2022) [CrossRef] [Google Scholar]
  5. B. Tusek, A. Jezovita, and P. Halar, “The Profitability Determinants of the Global Pharmaceutical & Biotechnology Companies During the Covid-19 Pandemic,” DIEM Dubrovnik Int. Econ. Meet., Vol. 6, No. 1, pp. 43– 54, (2021), doi:10.17818/diem/2021/1.5 [Google Scholar]
  6. T. E. Oamen, “Covid-19 Pandemic and Impact on Pharmaceutical Sales Representatives’ Operations in West Africa: A Socio- Demographic Case Study of Nigeria,” (2021). [Online]. Available: [Google Scholar]
  7. A. Yusuf, R. Pradipta, and N. C. Afif, “How to Respond the Pharmaceutical Company Market During the Covid-19 Pandemic (Study on PT . Fulky Hasya),” in International Sustainable Competitiveness Advantage 2020, (2020), pp. 703–708 [Google Scholar]
  8. G. Alcan, S. D. Guvenbas, and C. Ozdurak, “The Impact of Covid-19 to Global Pharmaceuticals and Biotechnology Company Stocks Returns,” Pressacademia, Vol. 9, No. 2, pp. 68–79, 2020, doi:10.17261/pressacademia.(2020).1215 [CrossRef] [Google Scholar]
  9. C. Behera and B. N. Rath, “The Covid-19 Pandemic and Indian Pharmaceutical Companies: An Event Study Analysis,” Bul. Ekon. Monet. dan Perbank., Vol. 24, pp. 1–14, (2021), doi: 10.21098/BEMP.V24I0.1483 [CrossRef] [Google Scholar]
  10. S. Mittal and D. Sharma, “The Impact of Covid- 19 on Stock Returns of the Indian Healthcare and Pharmaceutical Sector,” Australas. Accounting, Bus. Financ. J., Vol. 15, No. 1 Special Issue, pp. 5–21, (2021), doi: 10.14453/aabfj.v15i1.2 [CrossRef] [Google Scholar]
  11. I. K. Dewi and P. N. Kencana, “Dampak Pandemi Covid-19 Terhadap Kinerja Perusahaan Farmasi yang Terdaftar di BEI,” J. MADANI, Vol. 5, No. 1, pp. 54–67, (2022) [CrossRef] [Google Scholar]
  12. N. Qomariah and E. B. Satoto, “Improving Financial Performance and Profits of Pharmaceutical Companies During a Pandemic: Study on Environmental Performance, Intellectual Capital and Social Responsibility,” Qual. – Access to Success, Vol. 22, No. 184, pp. 154–165, (2021), DOI:10.47750/qas/22.184.20 [Google Scholar]
  13. V. S. Sullivan and S. Widoatmodjo, “Kinerja Keuangan Bank Sebelum Dan Selama Pandemi (COVID – 19),” J. Manajerial Dan Kewirausahaan, Vol. 3, No. 1, p. 257, (2021), DOI:10.24912/jmk.v3i1.11319 [CrossRef] [Google Scholar]
  14. S. Devi, N. M. S. Warasniasih, and P. R. Masdiantini, “The Impact of Covid-19 Pandemic on the Financial Performance of Firms on the Indonesia Stock Exchange,” J. Econ. Business, Account. Ventur., Vol. 23, No. 2, pp. 226–242(2020), doi: 10.14414/jebav.v23i2.2313, [Google Scholar]
  15. A. Wijayanto and A. H. D. Seno, “Comparative Analysis of Company Financial Performance Between Sub Sectors in The Consumer Goods Industry in Indonesia Before and During the Covid-19 Pandemic,” J. Econ. Financ. Manag. Stud., Vol. 04, No. 12, pp. 2427–2432, (2021), doi: 10.47191/jefms/v4-i12-03 [CrossRef] [Google Scholar]
  16. S. I. Ediningsih and A. Satmoko, “the Impact of the Covid-19 Pandemic on the Financial Performance of Pharmaceutical Companies Listed on Indonesia Stock Exchange,” Russ. J. Agric. Socio-Economic Sci., Vol. 119, No. 11, pp. 3–10, (2021), doi: 10.18551/rjoas.2021-11.01 [Google Scholar]
  17. Y. J. A. Febriantika, T. J. Prasetyo, and F. Dharma, “Analysis of Financial Performance and Company Value Before and during the Covid-19 Pandemic; Study on Manufacturing Companies Listed on IDX,” J. Dimens. Manag. Public Sect., Vol. 2, No. 3, pp. 62–68, (2021), doi: 10.48173/jdmps.v2i3.115 [CrossRef] [Google Scholar]
  18. G. Limbong, “Analysis of the Company ’ S Financial Performance Before And During the Covid-19 Pandemic (2019–2020) in Pharmaceutical Sector Companies Listed on the IDX,” J. Manaj., Vol. 10, No. 2, pp. 156–165, (2022). [CrossRef] [Google Scholar]
  19. E. Endri, D. Susanti, L. Hutabarat, T. P. Simanjuntak, and S. Handayani, “Financial Performance Evaluation: Empirical Evidence of Pharmaceutical Companies in Indonesia,” Syst. Rev. Pharm., Vol. 11, No. 6, pp. 803–816, (2020), doi: 10.31838/srp.2020.6.117 [Google Scholar]
  20. K. A. Fachrudin and H. Octavianus, “What Drives Value on Pharmaceutical Firms During the Covid-19 Pandemic?,” Miicema Xxi, Vol. 1, no. December, pp. 56–64, (2021) [Google Scholar]
  21. A. W. Fajriyanti and W. Wiyarni, “Corporate Financial Performance in the Covid-19 Pandemic,” Am. J. Ind. Bus. Manag., Vol. 12, No. 01, pp. 35–57, (2022), doi: 10.4236/ajibm.2022.121004 [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.